Michael P Lux

List of Publications by Year in descending order

104 papers	5,892 citations	117453 34 h-index	79541 73 g-index
117 all docs	117 docs citations	117 times ranked	9918 citing authors

#	ARTICLE	IF	CITATIONS
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
3	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
4	Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer, 2007, 109, 1905-1913.	2.0	316
5	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer, 2011, 11, 486.	1.1	260
6	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
7	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. PLoS ONE, 2012, 7, e29770.	1.1	219
8	Hereditary breast and ovarian cancer: review and future perspectives. Journal of Molecular Medicine, 2006, 84, 16-28.	1.7	149
9	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	1.3	145
10	Two different sides of 'chemobrain': determinants and nondeterminants of self–perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psycho-Oncology, 2010, 19, 1321-1328.	1.0	110
11	Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients. Onkologie, 2011, 34, 362-367.	1.1	106
12	Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. International Journal of Cancer, 2017, 140, 95-102.	2.3	99
13	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
14	Short–term effects of treatment–induced hormonal changes on cognitive function in breast cancer patients. Cancer, 2008, 113, 2431-2439.	2.0	83
15	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Research and Treatment, 2008, 112, 89-98.	1.1	77
16	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast, 2009, 18, 135-141.	0.9	76
17	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245.	0.8	72
18	Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. European Journal of Radiology, 2006, 60, 398-404.	1.2	71

#	ARTICLE	IF	CITATIONS
19	Characterizing mammographic images by using generic texture features. Breast Cancer Research, 2012, 14, R59.	2.2	65
20	Diabetes and prognosis in a breast cancer cohort. Journal of Cancer Research and Clinical Oncology, 2011, 137, 975-983.	1.2	59
21	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer, 2018, 18, 1051.	1.1	59
22	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast, 2018, 37, 154-160.	0.9	56
23	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€" Data from the German PRAEGNANT breast cancer registry. Breast, 2018, 37, 42-51.	0.9	54
24	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. Journal of Medical Internet Research, 2017, 19, e322.	2.1	48
25	Association of mammographic density with hormone receptors in invasive breast cancers: Results from a caseâ€only study. International Journal of Cancer, 2012, 131, 2643-2649.	2.3	44
26	The era of centers: the influence of establishing specialized centers on patientsâ€™ choice of hospital. Archives of Gynecology and Obstetrics, 2011, 283, 559-568.	0.8	43
27	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers, 2019, 11, 10.	1.7	43
28	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Archives of Gynecology and Obstetrics, 2017, 295, 1239-1245.	0.8	42
29	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 2019, 173, 319-328.	1.1	40
30	Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. Biochemical Pharmacology, 2012, 83, 480-488.	2.0	39
31	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer â€"Association With Patient and Disease Characteristics and Effect on Prognosis. Journal of Clinical Oncology, 2021, 39, 1619-1630.	0.8	39
32	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European Journal of Cancer, 2021, 155, 1-12.	1.3	39
33	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. JMIR Cancer, 2017, 3, e11.	0.9	38
34	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. Breast Cancer Research and Treatment, 2012, 135, 885-892.	1.1	36
35	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 175, 617-625.	1.1	35
36	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer â€" Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast, 2020, 54, 88-95.	0.9	34

#	Article	IF	Citations
37	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14.	0.8	32
38	The Hohl instrument for optimizing total laparoscopic hysterectomy: results of more than 500 procedures in a university training center. Archives of Gynecology and Obstetrics, 2012, 285, 123-127.	0.8	31
39	Filtration based assessment of CTCs and CellSearchÂ® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer, 2018, 18, 204.	1.1	30
40	Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. Breast Cancer Research and Treatment, 2013, 139, 429-440.	1.1	29
41	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock Breast Cancer: Reliability Study. Journal of Medical Internet Research, 2019, 21, e10004.	2.1	29
42	Hormone replacement therapy and prognosis in ovarian cancer patients. European Journal of Cancer Prevention, 2013, 22, 52-58.	0.6	28
43	The PI3K Pathway: Background and Treatment Approaches. Breast Care, 2016, 11, 398-404.	0.8	28
44	Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. European Journal of Cancer Prevention, 2007, 16, 216-224.	0.6	27
45	Are Certified Breast Centers Cost-Effective?. Breast Care, 2009, 4, 245-250.	0.8	27
46	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. Breast Cancer Research and Treatment, 2016, 158, 59-65.	1.1	27
47	Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Research and Treatment, 2009, 117, 305-317.	1.1	24
48	Pain perception and detailed visual pain mapping in breast cancer survivors. Breast Cancer Research and Treatment, 2010, 119, 105-110.	1.1	24
49	Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Breast, 2017, 32, 186-191.	0.9	24
50	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. Geburtshilfe Und Frauenheilkunde, 2017, 77, 870-878.	0.8	24
51	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Research and Treatment, 2013, 138, 899-908.	1.1	23
52	Update Breast Cancer 2018 (Part 2) â€" Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Und Frauenheilkunde, 2018, 78, 246-259.	0.8	23
53	Assessment of mammographic density before and after first full-term pregnancy. European Journal of Cancer Prevention, 2010, 19, 405-412.	0.6	21
54	Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. Archives of Gynecology and Obstetrics, 2016, 294, 343-351.	0.8	21

#	Article	IF	Citations
55	Update Breast Cancer 2018 (Part 1) â€" Primary Breast Cancer and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2018, 78, 237-245.	0.8	20
56	Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians. Breast Cancer Research and Treatment, 2012, 135, 811-820.	1.1	19
57	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer, 2014, 14, 66.	1.1	19
58	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. BMC Cancer, 2015, 15, 587.	1.1	19
59	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. International Journal of Cancer, 2016, 139, 1967-1974.	2.3	19
60	Update Breast Cancer 2017 â€" Implementation of Novel Therapies. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1281-1290.	0.8	19
61	Biosimilars in oncology: Effects on economy and therapeutic innovations. European Journal of Cancer, 2020, 139, 10-19.	1.3	19
62	The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Research and Treatment, 2007, 101, 95-104.	1.1	18
63	Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer â€" A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System. Onkologie, 2010, 33, 155-166.	1.1	18
64	Polymorphisms in the *RANK/RANKL* Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. BioMed Research International, 2014, 2014, 1-7.	0.9	18
65	Update Breast Cancer 2019 Part 4 â€" Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1079-1089.	0.8	18
66	Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. Breast, 2008, 17, 640-645.	0.9	16
67	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). Journal of Cancer Research and Clinical Oncology, 2017, 143, 541-550.	1.2	16
68	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. BMC Cancer, 2018, 18, 926.	1.1	16
69	Update Breast Cancer 2019 Part 5 â€" Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	0.8	16
70	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 174, 453-461.	1.1	15
71	Association of molecular subtypes with breast cancer risk factors. European Journal of Cancer Prevention, 2015, 24, 484-490.	0.6	14
72	Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. Archives of Gynecology and Obstetrics, 2013, 287, 337-344.	0.8	13

#	Article	IF	Citations
73	Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany. Archives of Gynecology and Obstetrics, 2021, 303, 521-531.	0.8	13
74	Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer. European Journal of Cancer Prevention, 2005, 14, 503-511.	0.6	12
75	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. Breast Care, 2012, 7, 364-369.	0.8	11
76	Financing of certified centers: a willingness-to-pay analysis. Archives of Gynecology and Obstetrics, 2013, 287, 495-509.	0.8	11
77	Comprehensive visualization of paresthesia in breast cancer survivors. Archives of Gynecology and Obstetrics, 2014, 290, 135-141.	0.8	11
78	Chylous ascites after lymphadenectomy for gynecological malignancies. Journal of Surgical Oncology, 2016, 114, 613-618.	0.8	11
79	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. Cancer Management and Research, 2021, Volume 13, 8457-8471.	0.9	10
80	Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study. Onkologie, 2010, 33, 360-368.	1.1	9
81	Factors influencing breast changes after pregnancy. European Journal of Cancer Prevention, 2013, 22, 259-261.	0.6	9
82	Update Breast Cancer 2018 (Part 3) â€" Genomics, Individualized Medicine and Immune Therapies â€" in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1110-1118.	0.8	8
83	Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers. European Journal of Cancer Prevention, 2006, 15, 474-479.	0.6	7
84	Mitomycin C in Patients with Gynecological Malignancies. Oncology Research and Treatment, 2010, 33, 547-557.	0.8	7
85	Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 176, 495-506.	1.1	7
86	Fulvestrant: A Further Treatment Option for Patients with Metastatic Uterine Cancer?. Oncology Research and Treatment, 2006, 29, 577-580.	0.8	6
87	The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2141-2149.	1.1	6
88	Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. European Journal of Medical Research, 2019, 24, 32.	0.9	6
89	Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. Oncotarget, 2017, 8, 78133-78143.	0.8	6
90	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. Breast Care, 2019, 14, 41-47.	0.8	5

#	Article	IF	Citations
91	Economic Constraints - the Growing Challenge for Western Breast Cancer Centers. Breast Care, 2013, 8, 41-47.	0.8	4
92	Best Supportive Care from the Conservative/Non-Surgical Perspective and Its Costs in the Treatment of Patients with Advanced Medullary Thyroid Cancer: Results of a Delphi Panel. Oncology Research and Treatment, 2014, 37, 316-322.	0.8	4
93	Update Breast Cancer 2021 Part 4 â€" Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2022, 82, 206-214.	0.8	4
94	Update Breast Cancer 2018 (Part 4) â€" Genomics, Individualized Medicine and Immune Therapies â€" in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1119-1128.	0.8	3
95	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients â€" a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	0.8	3
96	Real-world multi-country study of *BRCA1/2* mutation testing among adult women with HER2-negative advanced breast cancer. Future Oncology, 2022, 18, 1089-1101.	1.1	3
97	Clinical and Preclinical Experience with Gefitinib and Sunitinib. Breast Care, 2007, 2, 68-73.	0.8	2
98	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. Breast Care, 2021, 16, 291-298.	0.8	2
99	Health Economics in Breast Cancer. Breast Care, 2013, 8, 5-6.	0.8	1
100	Can a University Reproductive Medicine Centre Be Financed Under the Pre-Existing General Conditions in Germany?. Geburtshilfe Und Frauenheilkunde, 2019, 79, 63-71.	0.8	1
101	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics â€" A retrospective analysis of a real world registry. European Journal of Cancer, 2022, 172, 13-21.	1.3	1
102	Highlights from the Annual Meeting of the American Society of Clinical Oncology 2014 in Chicago - Expert Opinions Revisited. Breast Care, 2014, 9, 287-291.	0.8	0
103	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	0.8	0
104	Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany. Breast Care, 2021, 16, 1-9.	0.8	0